Last reviewed · How we verify
NCT07196189: Transmic-TCA
Effects of Fecal Microbiota Transplantation
trial testing Patients in Eating Disorders Symptoms in 84 participants. Currently enrolling.
16 November 2026
Quick facts
| Lead sponsor | University Hospital, Rouen |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 84 |
| Start date | 16 March 2022 |
| Primary completion | 16 November 2026 |
| Estimated completion | 16 April 2027 |
| Sites | 1 location across France |
Drugs / interventions tested
- Patients — full drug profile →
- healthy volunteer
Conditions studied
- Eating Disorders Symptoms — all drugs for Eating Disorders Symptoms →
Sponsor
University Hospital, Rouen
Who can join
Adults 18 to 50, any sex, with Eating Disorders Symptoms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The intestinal microbiota plays an essential role in digestion and, through the gut-brain axis, in the regulation of weight gain and eating behavior. The balaEating disorders (EDs) are serious pathologies affecting adolescence and young adults, likely to become chronic, with long-term morbidity and mortality impacts. These pathologies represent a very important public health issue. EDs are defined by the DSM-V classification criteria and include different forms: anorexia nervosa, bulimia nervosa, hyperphagia, and atypical or unspecified forms. The global prevalence of these diseases reaches 8.4% in women and 2.2% in men. These eating disorders lead to numerous psychiatric and somatic complications and have a significant impact on the quality of life and mortality of patients (particularly in anorexic patients). The molecular mechanisms underlying eating disorders are still poorly understood. The etiological origin of these diseases is complex and involves various biological, psychological, and sociocultural factors. The intestinal microbiota, which corresponds to the community of microorganisms living inside the intestine, could be one of these factors. Indeed, the microorganisms of the microbiota interact very closely with intestinal cells but also with distant organs, such as the brain, via nerve communications or the bloodstream. nce and dialogue between the intestinal microbiota and human cells can be altered following changes in the environment, diet, or stress. These disturbances, found among others in patients suffering from eating disorders, can lead to a lasting change in the composition or metabolic activity of the microbiota (dysbiosis), which can have profound repercussions on human physiology. Several clinical studies conducted on patients with anorexia have highlighted the existence of intestinal dysbiosis in these individuals. As with anorexia, the potential role of intestinal dysbiosis in bulimic and binge eating patients remains currently unknown. This dysbiosis could have a harmful effect on intestinal physiology and promote the onset of functional digestive disorders, which are frequently found in patients suffering from eating disorders. This dysbiosis could also lead to a disruption of communication along the gut-brain axis and contribute to the eating disorders observed in these patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07196189
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Patients
Trials testing the same drug.
- NCT06417827 — Artificial Intelligence for Mental Health Diagnoses and Treatment Plans: A Protocol for Actors and Patients · NA · unknown
- NCT05175755 — Genetic Risk Factors Predictive of the Occurrence of Maternally Diagnosed Perinatal Depression in Women · NA · unknown
- NCT05613712 — Chronic Inflammatory Rheumatism: Management of Comorbidities in Ambulatory Medicine · completed
- NCT05461521 — Improving FAMily Members' Experience in the ICU · completed
- NCT05692726 — Evaluation of Volume and Electrolyte Balance in Hyponatremia Treatment - a Prospective Observational Trial · recruiting
Other recruiting trials for Eating Disorders Symptoms
Currently open trials in the same condition.
- NCT07295197 — Oral Indicators for ED Screening · recruiting
Other University Hospital, Rouen trials
Trials by the same sponsor.
- NCT07441564 — Evaluation of the Efficacy of Ischemic Preconditioning to Protect Against Acute Kidney Injury After Open Surgery for Jux · NA · not yet recruiting
- NCT07535944 — Prospective Exploration of Vascular Complications Associated With the Use of Immune Checkpoint Inhibitors · not yet recruiting
- NCT07464184 — Evolution of Hypoxic Burden and Sympathetic/Parasympathetic Balance in Patients With Pulmonary Hypertension · NA · not yet recruiting
- NCT07359885 — Prediction of Postoperative Pulmonary Complications in Thoracic Surgery · not yet recruiting
- NCT07247500 — Impact of Reventilation After One-Lung Ventilation in Thoracic Surgery (OLVREEXP) · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07196189 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Rouen
- Last refreshed: 29 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07196189.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing